Aldeyra Therapeutics Inc (NASDAQ:ALDX) announced recently the positive results from its Phase 2a clinical trial of topical ocular (ADX-102) for treatment of patients with a dry eye condition. The ADX-102 is a potential agent that treats dry eye disease, a complex medical condition affecting about 20 million people in the US. The disease causes discomfort, inflammation, and impaired vision in severe cases.
The shares of the company ascended to 53% up to $6.50 immediately after the announcement. John Sheppard, a professor of Ophthalmology at Eastern Virginia Medical School stated that the presence of a rapid-onset activity and tolerability profile is evidence that Phase 2a clinical trial of ADX-102 may bring significant benefits to patients compared to the current therapies. The data reveals the possibility of applying ADX-102 as an essential and high-quality therapy in ophthalmology.
Todd C. Brady, the CEO of Aldeyra affirmed that they are impressed by the prospective results for the dry eye disease, which is basically perceived to be complex in treating and accounts for over $1.8 billion in drug prescription sales in the US. The company intends to use the data from the study to launch Phase 2b clinical trial of the disease in the first half of next year.
The aim of the clinical trial for ADX-102 was to select the best formulation and preferable dose range for the next Phase 2b clinical trial which will launch in 2018. After the trials, there were no safety issues and serious adverse occurrences reported after the administration of ADX-102 in patients who participated in the study.
The Phase 2a data signifies the fourth set of positive Phase 2 findings with the ADX-102 treatment in topical ocular inflammation. Aldeyra is committed to improving the patient’s lives by researching and developing advanced products that treat diseases related to pro-inflammatory and toxic molecular elements. ADX-102 which is the company’s lead product candidate has been tested in more than 250 patients suffering from allergic conjunctivitis, noninfectious anterior uveitis, and dry eye disease.
